08 Febuary 2006

Winners of Made in Sheffield Award

The Medical House plc (“TMH”), (AIM:MLH) is pleased to announce that it has received the 2005 Made in Sheffield Award at a ceremony attended by Home Secretary Charles Clarke, in the city last night.

The Made in Sheffield Award is presented to the company judged to have developed the product, process or service most likely to enhance Sheffield’s worldwide reputation for quality, ingenuity and innovation.

TMH’s development of novel injection technologies, combined with its continual innovation in the field of orthopaedic instruments, were recognised by the judging panel in its selection of TMH as winners of the award. TMH’s ASI disposable autoinjector technology was highlighted for its potential role in responding to natural disasters and in helping to avert the spread of pandemics. TMH had announced last week that Martindale Products and Specials (a division of Cardinal Health Inc.) is its first pharmaceutical company partner for supply of the ASI.

In accepting the award, The Medical House Chairman, Ian Townsend said:
“It is an honour to receive such a prestigious award. What we have achieved has only been made possible by the hard work and dedication of the people within The Medical House group.”

For further information:
The Medical House PLC tel: 0114 261 9011
Ian Townsend, Chairman www.themedicalhouse.com

Notes to Editors:

About The Medical House (TMH)
TMH’s first needle-based injection system the ASI, followed on from the development of a range of needle-free devices which are already successfully used for delivery of insulin.

In December 2005, TMH announced an agreement with a European Government Agency to develop a solution for emergency application of particular pharmaceutical products. Within this project, TMH’s client will make the required capital investment and cover the costs of design and development.

In September 2004, TMH signed an agreement with Serono to develop and supply with a new needle free system for use with their human growth hormone. The market for human growth hormone drugs is expected to reach $2.2 billion by 2006 according to AS Insights.

In February 2005, TMH announced a 10-year agreement which it has signed with BioPartners GmbH, to supply its GH-1 needle-free system for the delivery of BioPartners’ human growth hormone products.

TMH also has several distribution agreements in place for the insulin market for its range of reusable needle-free insulin injectors and in November 2002 it announced that it had received approval from the PPA (Prescription Pricing Authority) for the admission of its first needle-free insulin delivery device to the NHS Drug Tariff. This has enabled the device and the related consumables to be prescribed on a free-of-charge basis to more than 500,000 people with diabetes in the UK who inject insulin daily. This was the first needle-free injection system for liquid pharmaceuticals to be available on the UK NHS Drug Tariff.

Historically, the majority of the Group’s turnover has come from its orthopaedic company, Eurocut Limited. It designs and manufactures instruments and systems used in orthopaedic procedures for many of the world’s leading orthopaedic companies. Eurocut was established in 1988 and now has a reputation as one of Europe’s leading orthopaedic instrument businesses which has benefited from increasing demand for complex instrumentation to carry out minimally invasive and image guided surgical procedures.